Press release
Samsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share
Read moreCreating the future in peptides
We lead innovation in peptide API’s to the benefit of millions of patients
Contact usMarket leader in peptide API manufacturing and services
PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) supporting pharmaceutical and biotech companies in the development and manufacturing of proprietary and generic active pharmaceutical ingredients (API).
Provisional interim result of the public tender offer of Samsung Biologics Co., Ltd.
13 Oct 2026 - Baar, Switzerland, 13 October 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the provisional interim […]
Read morePolyPeptide publishes the invitation to its extraordinary general meeting of shareholders on 26 October 2026
2 Oct 2026 - Baar, 2 October 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, published the invitation to its extraordinary general […]
Read more